Navigation Links
Abbott to Present Data on Market-Leading XIENCE V® and Promising Vascular Pipeline at TCT 2010
Date:9/16/2010

TCT 2010    

-- XIENCE V Data From the SPIRIT IV Trial to be Presented as a Late Breaking Trial on Sept. 23-- Abbott's Vascular Pipeline Presentations to Include Data on the MitraClip® System and the Bioresorbable Vascular Scaffold

ABBOTT PARK, Ill., Sept. 16 /PRNewswire-FirstCall/ --  Abbott (NYSE: ABT) today announced the company's schedule of key data presentations at the Cardiovascular Research Foundation's 22nd annual Transcatheter Cardiovascular Therapeutics (TCT) scientific symposium in Washington, D.C., to be held Sept. 21 – 25. Highlights include late-breaking two-year data from SPIRIT IV, one of the largest randomized, head-to-head clinical trials between two drug eluting stents – Abbott's XIENCE V® Everolimus Eluting Coronary Stent System and Boston Scientific's TAXUS® Express Paclitaxel-Eluting Coronary Stent System. In addition, the company will present data on two key pipeline products: the first-of-its-kind MitraClip® system, an investigational device in the United States; and the bioresorbable vascular scaffold (BVS), currently under clinical investigation outside the United States.

"We continue to strengthen our leadership position in the treatment of vascular disease with significant new data that support our market-leading XIENCE V stent, which has become the gold standard of drug eluting stents around the world," said Robert Hance, senior vice president, vascular, Abbott. "We also continue to make progress with our industry leading vascular pipeline, and we look forward to presenting additional data on our key pipeline products, including the MitraClip system and our bioresorbable vascular scaffold."

Key presentations are as follows (all times are Eastern):

SPIRIT IV: Two-year results from SPIRIT IV will be presented by Gregg W. Stone, M.D.
'/>"/>

SOURCE Abbott
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. Abbott Receives Supplemental FDA Approval for its Best-in-Class in Sensitivity RealTime HIV-1 Viral Load Test
2. Abbott and AstraZeneca Announce Selection of Next-Generation Fenofibrate ABT-335 and CRESTOR(R) Fixed-Dose Combination
3. Abbott Initiates Clinical Study to Evaluate Use of RX Herculink(R) Elite(TM) Renal Stent System for the Treatment of Renal Artery Stenosis
4. Abbotts ABT-874 Shows Positive Results for Maintenance of Response in Phase II Psoriasis Study
5. Abbotts XIENCE(TM) V Everolimus Eluting Coronary Stent Shows Continued Superiority to TAXUS Stent in Reducing Major Adverse Cardiac Events in SPIRIT III Clinical Trial
6. Abbott Announces Positive One-Year Results from the Worlds First Clinical Trial of a Fully Bioabsorbable Drug Eluting Coronary Stent
7. Abbotts m2000(TM) Molecular Diagnostic Instrument and RealTime HIV-1 Test Win Chicago Innovation Award
8. Abbotts HUMIRA(R) (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis
9. Abbotts XIENCE(TM) V Drug Eluting Stent Demonstrates Consistent and Positive Clinical Outcomes Out to Two Years
10. Abbotts Phase III Studies of Investigational TriLipix(TM) (ABT-335), in Combination With Statins, Meets Primary Endpoints on Improving LDL, Triglycerides and HDL
11. Study in JAMA Shows Patients Treated With Abbotts XIENCE(TM) V Drug Eluting Stent Experience Better Outcomes Than Patients Treated With Market-Leading Drug Eluting Stent
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... PALM BEACH GARDENS, Fla. , Jan. 15, 2014  In an ... C. difficile and TB in ambulances and other transport vehicles, an ... being used by rescue personnel for the first time. ... coming in contact with these deadly pathogens, West Palm ...
(Date:1/15/2014)... 2014  Echo Therapeutics, Inc. (Nasdaq: ECTE ) ... System as a non-invasive, wireless continuous glucose monitoring system, ... Chairman and Interim CEO of Echo Therapeutics, will present ... Conference. Mr. Doman will make a ...
(Date:1/15/2014)... NEW YORK , Jan. 15, 2014 ... research report is available in its catalogue: ... & Forecast – Worldwide Analysis ... Pump Market Analysis ...
Breaking Medicine Technology:Superbugs No Longer Ride In Rescue Vehicles 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 2Echo Therapeutics to Present at the Noble Financial Capital Markets' Tenth Annual Equity Conference 3Insulin Pump Market & Forecast - Worldwide Analysis 2Insulin Pump Market & Forecast - Worldwide Analysis 3Insulin Pump Market & Forecast - Worldwide Analysis 4Insulin Pump Market & Forecast - Worldwide Analysis 5Insulin Pump Market & Forecast - Worldwide Analysis 6Insulin Pump Market & Forecast - Worldwide Analysis 7Insulin Pump Market & Forecast - Worldwide Analysis 8Insulin Pump Market & Forecast - Worldwide Analysis 9Insulin Pump Market & Forecast - Worldwide Analysis 10Insulin Pump Market & Forecast - Worldwide Analysis 11Insulin Pump Market & Forecast - Worldwide Analysis 12Insulin Pump Market & Forecast - Worldwide Analysis 13Insulin Pump Market & Forecast - Worldwide Analysis 14Insulin Pump Market & Forecast - Worldwide Analysis 15Insulin Pump Market & Forecast - Worldwide Analysis 16Insulin Pump Market & Forecast - Worldwide Analysis 17
... April 18, 2012  CAQH® announced today that ... the Universal Provider Datasource® (UPD®), demonstrating that ... standard for self-reported provider data used to ... network directories, referrals and claims administration. ...
... Live has revealed further details of the newest event ... (SEA) 2012. Set to debut from 10-12 May 2012 at ... first trade show and exhibition of its kind to be ... CPhI SEA will provide a meeting place ...
Cached Medicine Technology:One Million Healthcare Providers Now Use the CAQH Universal Provider Datasource 2One Million Healthcare Providers Now Use the CAQH Universal Provider Datasource 3Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 2Leading Pharma Ingredients Event Debuts in Growing ASEAN Market 3
(Date:4/24/2014)... influenza pH1N1 virus caused the first flu pandemic in ... 2009 and killed more than 50 people in the ... during flu epidemics (winter/spring seasons). , Infections with ... illnesses. World Health Organization has recommended Tamiflu for treatment ... of this drug is that it targets viral proteins ...
(Date:4/23/2014)... from healthy, unrelated donors was safe and effective ... by Clostridium difficile , according to a ... Diseases and available online. Known as fecal ... given via a colonoscope or a nasogastric tube. ... promising treatment more readily available to patients. , ...
(Date:4/23/2014)... Washington State University Spokane have developed a new ... nod off behind the wheel. , Their recently ... are more variable in drowsy driversand offers an ... video-based driver drowsiness detection systems. , Van Dongen"Video-based ... car is drifting out of its lane are ...
(Date:4/23/2014)... April 23, 2014 The American Society for Radiation ... Role of Postoperative Radiation Therapy for Endometrial Cancer: ... of adjuvant radiation therapy in the treatment of ... in the May-June 2014 issue of Practical ... journal of ASTRO. The full-length guideline is available ...
(Date:4/23/2014)... pathway that helps prevent new cells from receiving too ... been directly linked to cancer and other diseases. , ... the end of cell division, the enzyme Cdc14 activates ... are fully repaired before the parent cell distributes copies ... safeguard against some of the most devastating genome errors, ...
Breaking Medicine News(10 mins):Health News:Pilot study suggests ways to widen access to fecal transplants for C. diff infections 2Health News:WSU innovation improves drowsy driver detection 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 2Health News:ASTRO issues guideline on the role of postoperative radiation therapy for endometrial cancer 3Health News:Study identifies enzymes that help fix cancer-causing DNA defects 2
... Endocrine Society,s Journal of Clinical Endocrinology & Metabolism ... corn syrup for two weeks as 25 percent of their ... triglycerides, which have been shown to be indicators of increased ... that people consume only five percent of calories as added ...
... interpret mammograms does not improve accuracy, according to a study ... National Cancer Institute. CAD software, used currently ... States, identifies patterns associated with breast cancers and marks potential ... recommendation. To learn whether CAD leads to ...
... , WEDNESDAY, July 27 (HealthDay News) -- Scientists who sequenced the ... the deadly food poisoning outbreak in Germany that began in May ... paper was published online July 27 in the New England ... the reasons why this particular strain of E. coli ...
... , WEDNESDAY, July 27 (HealthDay News) -- Many ... behavioral issues often face tough social and academic troubles ... the progress of more than 1,450 students in fourth ... found that one-third coped with special health care needs ...
... Using human breast cancer cells and the protein that causes fireflies ... some breast cancer cells become resistant to the anticancer effects of ... "dimmer switches" that apparently control how a breast cancer gene responds ... July 7 by Human Molecular Genetics , the scientists show ...
... food restaurants and other outlets that sell junk food in your ... burgers and fries and wash them down with a soda. ... from the UCLA Center for Health Policy Research that examined the ... junk food consumption. The upshot? Nearly three-quarters of ...
Cached Medicine News:Health News:Fructose consumption increases risk factors for heart disease 2Health News:Computer-aided detection does not improve mammogram accuracy 2Health News:Gene Study Sheds Light on Deadly German E. Coli Strain 2Health News: Special Needs Kids Bullied More, Fare Poorly at School 2Health News: Special Needs Kids Bullied More, Fare Poorly at School 3Health News:Johns Hopkins researchers discover how some breast cancers alter their sensitivity to estrogen 2Health News:As unhealthy food outlets multiply, teens eat more junk 2
... in Canons DR innovations, the CXDI-31 is ... a compact and lightweight design, the Canon ... conventional screen-film cassettes. It is designed to ... to get with fixed devices and supports ...
... a cost-effective synthetic bone filler tailored ... Phosphate (TCP) and Hydroxyapatite (HAP), its ... BAB formulates the chemistry and microstructure ... This formulation provides optimal osteo-conduction. The ...
The Oscor PACE 101 H is an external single chamber cardiac demand pacemaker. The PACE 101 H feature an option for a atrial overdrive stimulation....
... TAU Lead is a ... stimulation lead for temporary ... The unique shaft design ... straight or preformed stylets ...
Medicine Products: